Login to Your Account

Other News To Note

Thursday, November 29, 2012

• Cadence Pharmaceuticals Inc., of San Diego, and Perrigo Co., of Allegan, Mich., with its subsidiary, Paddock Laboratories LLC, agreed to resolve pending patent litigation over Ofirmev (acetominophen) injection. Under the settlement, the lawsuit filed by Cadence in the U.S. District Court for the District of Delaware related to Paddock's abbreviated new drug application filing with the FDA will be dissmissed with prejudice. Litigation against Exela Pharma Sciences LLC, Exela PharmaSci Inc. and Exela Holdings Inc. will continue.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription